Bisphosphonate - related osteonecrosis of the jaws: the point of view of the oral pathologist.
- 1 January 2007
- journal article
- Vol. 4 (1) , 53-7
Abstract
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is mainly reported in patients with bone metastasis from a variety of solid tumors and disseminated multiple myeloma receiving iv bisphosphonates therapy. These patients represent 95% of reported cases. The reported incidence of BRONJ is significantly higher with the iv preparations zoledronic acid and pamidronate while the risk appears to be minimal for patients receiving oral bisphosphonates. Currently, available published incidence data for BRONJ are based on retrospective studies and estimates of cumulative incidence range from 0.8% to 12%. The mandible is more commonly affected than the maxilla (2:1 ratio), and 60% of cases are preceded by a dental surgical procedure. The signs and symptoms that may occur before the appearance of clinical evident osteonecrosis include changes in the health of periodontal tissues, non-healing mucosal ulcers, loose teeth and unexplained soft-tissue infection. Although the definitive role of bisphosphonates remains to be elucidated, the alteration in bone metabolism together with surgical insult or prosthetic trauma appear to be key factors in the development of BRONJ. Tooth extraction as a precipitating event is a common observation in the reported literature. The significant benefits that bisphosphonates offer to patients clearly outbalance the risk of potential side effects; however, any patient for whom prolonged bisphosphonate therapy is indicated, should be provided with preventive dental care in order to minimize the risk of developing this severe condition. This article provides a review of current developments about the pathogenetic, clinical, management and preventive aspects of BRONJ.Keywords
This publication has 33 references indexed in Scilit:
- International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patientsEuropean Journal of Cancer, 2007
- Osteonecrosis of the Jaw — Do Bisphosphonates Pose a Risk?New England Journal of Medicine, 2006
- Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancerAnnals of Oncology, 2006
- Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatmentThe Lancet Oncology, 2006
- Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk FactorsJournal of Clinical Oncology, 2006
- Bisphosphonate‐associated osteonecrosis of the auditory canalBritish Journal of Haematology, 2005
- Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatmentJournal of Clinical Periodontology, 2005
- Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four‐case reportJournal of Oral Pathology & Medicine, 2005
- Bisphosphanates and Oral Cavity Avascular Bone NecrosisJournal of Clinical Oncology, 2003
- Phosphorus necrosis of the jaw: 'phossy jaw'British Dental Journal, 1972